Research Update CHF 02534 EY 4 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma

We have screened 58 dogs for the study. None of the dogs were enrolled due to the detection of metastatic disease during the screening process. Two other dogs were not screened due to the prior use of Yunnan Baiyao beyond the 24-hour limit allowed, and another owner cancelled the morning of the screening for unknown reasons. We have enrolled 19 dogs to date, bringing enrollment to 95% of the dogs proposed for the study. Continue reading “Research Update CHF 02534 EY 4 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma”

Research Update CHF 02806-MOU EY3: Strategic Prevention of Canine Hemangiosarcoma: Lifetime Follow-Up

The goal for this project is to develop a reliable, accessible, and actionable test to identify dogs at risk for hemangiosarcoma during the earliest stages of disease and to use a strategic, rationally designed approach to prevent its occurrence in these high-risk dogs before it becomes clinically detrimental and life-threatening. Continue reading “Research Update CHF 02806-MOU EY3: Strategic Prevention of Canine Hemangiosarcoma: Lifetime Follow-Up”

Research Update CHF 02783 FINAL: Transcriptional Profiling of Canine Soft Tissue Sarcoma

Soft tissue sarcoma (STS) encompasses a number of neoplasms that are derived from mesenchymal cells including fibrosarcoma, myxosarcoma, hemangiopericytoma, and undifferentiated sarcoma. In the dog, STSs arise frequently in the dermis/subcutis and represent up to 15% of the neoplasms in this location. Our primary aim of this grant was to collect cases of canine STS for histologic and gene expression analysis which we have completed. During all three years of the grant, we had excellent recovery rates from formalin-fixed tissue and have begun to generate sequencing data that can be layered onto the histologic findings and patient demographics.

FINAL, Research Update Transcriptional Profiling of Canine Soft Tissue Sarcoma

Research Update CHF 02780 FINAL: Bladder Carcinogen Exposures in Pet Dogs

Bladder cancer case recruitment is complete, assisted by a collaboration with Antech, which attached our study flyer to all BRAF urine tests that were positive for canine bladder cancer. We are awaiting the last batch of analyses for urinary chemicals (acrolein and arsenic) in dogs and their owners, as well as measurements of arsenic in tap water and household dust, and acrolein in household air. We hypothesize that these chemical exposures will be higher in bladder case homes compared to control homes. Continue reading “Research Update CHF 02780 FINAL: Bladder Carcinogen Exposures in Pet Dogs”

Research Update CHF 02519 Final: Prevalence of Bartonella spp. Infection in Dogs with Cardiac and Splenic Hemangiosarcomas Within and Between Geographic Locations

We gained substantial and seemingly important information relative to the aims of this study. We were able to obtain the initial set of samples on April 26, 2018 so we had a short delay in starting this study. Subsequently, the COVID epidemic and loss of research personal resulted in repeated interruptions in our research efforts. After completing all Year I study aims, we continued to work on improvements in immunohistochemistry and FISH localization of Bartonella organisms within various cell types. Continue reading “Research Update CHF 02519 Final: Prevalence of Bartonella spp. Infection in Dogs with Cardiac and Splenic Hemangiosarcomas Within and Between Geographic Locations”

Research Update CHF 02758 FINAL: Optical Coherence Tomography for Margin Evaluation of Canine Skin and Subcutaneous Neoplasms

Thank you for supporting our project titled “Optical coherence tomography for margin evaluation of skin and subcutaneous neoplasms”. This project is investigating an emerging diagnostic imaging tool, optical coherence tomography that uses light waves to generate real time high-resolution images of tissues for detection of residual cancer cells immediately following surgical removal. Our team involves collaboration between veterinary medicine and pathology at the Ohio State University. We have completed enrollment of the 80 cases. We completed the first phase of this project where we are looking at imaging skin tumors after surgical removal in dogs. Continue reading “Research Update CHF 02758 FINAL: Optical Coherence Tomography for Margin Evaluation of Canine Skin and Subcutaneous Neoplasms”

Research Update CHF 02783 MY3: Transcriptional Profiling of Canine Soft Tissue Sarcoma

Soft tissue sarcoma (STS) encompasses a number of neoplasms that are derived from mesenchymal cells including fibrosarcoma, myxosarcoma, hemangiopericytoma, and undifferentiated sarcoma. In the dog, STSs arise frequently in the dermis/subcutis and represent up to 15% of the neoplasms in this location. Our primary aim of this grant was to collect cases of canine STS for histologic and gene expression analysis. Continue reading “Research Update CHF 02783 MY3: Transcriptional Profiling of Canine Soft Tissue Sarcoma”

Research Update CHF 02780 MY3: Bladder Carcinogen Exposures in Pet Dogs

Bladder cancer case recruitment has been steady through our alliance with Antech, which is attaching our study flyer to all BRAF urine tests that are positive for bladder cancer. We are now enrolling 2-3 dogs with bladder cancer per month. We also have a list of possible matched controls through our expanded outreach through Facebook. We have recorded questionnaire data encoded for all dog kits that have been returned to us. Continue reading “Research Update CHF 02780 MY3: Bladder Carcinogen Exposures in Pet Dogs”

Research Update CHF 02772 FINAL: Identifying Early Stage Ultra-rare Mutations as Predictive Biomarkers of Lymphoma in High-risk versus Low-risk Breeds Within the Dog Aging Project

The primary goal of this project is to test the hypothesis that breeds vary in risk of lymphoma due, at least in part, to breed-specific variation in rates of mutation in genes relevant to lymphoma. To test this hypotheses, we needed to gather blood samples from breeds at high risk and low risk of lymphoma, and from individuals of different ages within those breeds. We would then measure the frequency of rare mutations in several genes, and ask if this frequency is higher in breeds at relatively high risk of lymphoma. Continue reading “Research Update CHF 02772 FINAL: Identifying Early Stage Ultra-rare Mutations as Predictive Biomarkers of Lymphoma in High-risk versus Low-risk Breeds Within the Dog Aging Project”